Non-animal Alternative Testing Market – By Product, By Method, By Technology, By Application, By End Use, & Global Forecast, 2024 – 2032

Key players in the industry include AlveoliX, BICO GROUP, CN Bio Innovations, Emulate, Hesperos, InSphero, Lonza Group, Merck, MIMETAS, Thermo Fisher Scientific, TissUse, and VITROCELL Systems.

Increasing public awareness and ethical concerns about animal testing are driving pharmaceutical companies to adopt non-animal testing methods, influenced by consumer demand for more humane research practices.

The U.S. non-animal alternative testing industry is forecasted to reach USD 1.9 million by 2032, having dominated the North American market with a revenue of USD 656.6 million in 2023.

The global non-animal alternative testing industry was valued at approximately USD 1.8 billion in 2023 and is estimated to grow at an 11.9% CAGR from 2024 to 2032, driven by increasing investments and research grants for alternative technologies.

The cell lines segment dominated the market in 2023, accounting for USD 1.2 billion, due to their extensive use in drug development, toxicity testing, and biological research.